Atara Biotherapeutics (NASDAQ:ATRA) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report issued on Friday,Benzinga reports. The firm set a “buy” rating and a $25.00 price target on the biotechnology company’s stock. Rodman & Renshaw’s price target would suggest a potential upside of 151.76% from the company’s current price.

Other equities analysts have also recently issued research reports about the company. TD Cowen raised Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Canaccord Genuity Group lifted their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Atara Biotherapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Atara Biotherapeutics Price Performance

ATRA stock opened at $9.93 on Friday. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50. The stock has a market capitalization of $57.20 million, a price-to-earnings ratio of -0.39 and a beta of 0.55. The company has a 50-day moving average of $10.73 and a two-hundred day moving average of $9.63.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) earnings per share. Equities analysts expect that Atara Biotherapeutics will post -12.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several large investors have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in Atara Biotherapeutics during the second quarter worth about $79,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics in the 2nd quarter valued at $53,000. FMR LLC raised its position in Atara Biotherapeutics by 41.7% in the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the last quarter. Vestal Point Capital LP boosted its stake in Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Finally, State Street Corp increased its position in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.